National Institutes of Health (NIH)
Bethesda
MD
United States
332 articles about National Institutes of Health (NIH)
-
National Institutes of Health Names CHOP, Penn an Undiagnosed Diseases Network Site
9/24/2018
The National Institute of Health (NIH) has named Children's Hospital of Philadelphia and the Hospital of the University of Pennsylvania (HUP) as one of the newest sites of its Undiagnosed Diseases Network (UDN), awarding the two institutions $2.5 million in research grants.
-
The U.S. Food and Drug Administration is hoping to fill numerous vacancies at the regulatory agency. In June, the FDA laid out some of its hiring needs, as well as its approach to attracting top-quality talent in a report to Congress.
-
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
-
Debate Over the Orphan Drug Act Heats Up
8/30/2018
Recently, Milton Packer, a renowned cardiologist at Baylor Scott & White Health, wrote a criticism of the Orphan Drug Act and the resulting problems caused by the biopharma industry. John LaMattina, formerly president of Pfizer Global Research and Development and a current senior partner at PureT... -
Citing safety concerns, a watchdog organization is calling on the National institutes of Health to halt enrollment in a clinical trial evaluating a treatment for sepsis that the organization said is risky and flawed.
-
Companies Continue to Take Aim at Glioblastoma, a Cancer Highlighted by the Death of Sen. John Mc...
8/27/2018
McCain died Saturday after deciding to discontinue treatment for brain cancer. He approached the end of his life in the same manner in which he approached me that day in Raleigh – with the strength of character. -
The NIH’s National Institutes on Aging (NIA) and the Alzheimer’s Association brought together various experts and stakeholders to create the National Strategy for Recruitment and Participation in Alzheimer’s Disease Clinical Research.
-
Days after it closed on a $42 million Series A funding round, Karuna Pharmaceuticals has named a new chief executive officer. The company appointed industry veteran and founder of Sage Therapeutics Steven Paul as its new top officer.
-
Primetime awarded SBIR Fast-Track grant to develop a novel anti-depressant treatment
8/13/2018
Primetime Life Sciences, LLC, a pharmaceutical company focused on discovery and development of new and smart treatments by using a multi-disciplinary, highly collaborative "bench-to-bedside" approach, today announced it has been awarded a Fast-Track Small Business Innovation Research (SBIR) grant by the National Institute of Health for development of depression.
-
Mustang Bio and St. Jude Children’s Research Hospital Enter into Exclusive Worldwide License Agreement for a Ground-Breaking, Clinical-Stage Lentiviral Gene Therapy with Curative Potential for X-linked Severe Combined Immunodeficiency
8/13/2018
Mustang Bio, Inc., a Fortress Biotech Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology, and St. Jude Children’s Research Hospital, the nation’s leading hospital dedicated to understanding, treating and curing childhood cancer and other life-threatening diseases, announced today that they have partnered.
-
Emergent BioSolutions, headquartered in Gaithersburg, Maryland, inked a deal to buy PaxVax, based in Redwood City, California, for $270 million in cash.
-
The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter—basically a rejection—to Austin, Texas-based Pain Therapeutics for Remoxy ER for pain.
-
Primetime entered into a CRADA with NIH/NCATS to develop antimicrobial agents for antimicrobial resistant infections
8/3/2018
Primetime Life Sciences, LLC has signed a Collaborative Research and Development Agreement (CRADA) with the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH).
-
Research published in the journal Nature by researchers at the National Health Research Institutes in Taiwan and the National Institute on Aging, National Institutes of Health in the U.S. suggest that a class of diabetes medications known as GLP-1 analogues may be effective treatments for Parkins...
-
Ultragenyx Announces First Patient Dosed in Phase 1/2 study of DTX401, a Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa); FDA Grants Fast Track Designation to Gene Therapy Program
7/26/2018
Ultragenyx Pharmaceutical Inc.(NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that the first patient has been dosed in the Phase 1/2 study of DTX401, an adeno-associated virus vector based gene therapy for the treatment of patients with glycogen storage disease type Ia (GSDIa).
-
A report recently published by the National Academies of Sciences, Engineering, and Medicine concluded that institutions and researchers should regularly and carefully evaluate whether and how to provide study results to participants.
-
The UK’s Wellcome Trust, a charitable foundation, announced it is creating the $330 million Leap Fund to invest in high-risk healthcare and life science research.
-
MaxCyte and U.S. National Institutes of Health's National Heart, Lung, and Blood Institute Enter Cooperative Research & Development Agreement for Sickle Cell Disease
6/11/2018
Under this agreement, MaxCyte's second signed with a U.S. NIH institute in the past year, the Company and the National Heart, Lung, and Blood Institute will explore development of new therapies for sickle cell disease using MaxCyte's gene-correction platform
-
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) launched an educational suite dubbed the “Parkinson’s Clinical Trial Companion.”
-
Inovio and The Wistar Institute Receive More Than $4.6M in R&D Funding to Advance Vaccines Against Tuberculosis & Malaria
2/12/2018
The grants were from the Bill & Melinda Gates Foundation and the (NIH.